3-Iodobenzoyl naltrexamine (IBNtxA) is a potent analgesic belonging to the pharmacologically diverse 6β-amidoepoxymorphinan group of opioids. We present the synthesis and pharmacological evaluation of five analogs of IBNtxA. The scaffold of IBNtxA was modified by removing the 14-hydroxy group, incorporating a 7,8 double bond and various N-17 alkyl substituents. The structural modifications resulted in analogs with picomolar affinities for opioid receptors. The lead compound (MP1104) was found to exhibit approximately 15-fold greater antinociceptive potency (ED50 = 0.33 mg/kg) compared with morphine, mediated through the activation of kappa- and delta-opioid receptors. Despite its kappa agonism, this lead derivative did not cause place aversion or preference in mice in a place-conditioning assay, even at doses 3 times the analgesic ED50. However, pretreatment with the lead compound prevented the reward behavior associated with cocaine in a conditioned place preference assay. Together, these results suggest the promise of dual acting kappa- and delta-opioid receptor agonists as analgesics and treatments for cocaine addiction.
3-Iodobenzoyl naltrexamine (n class="Chemical">IBNtxA) is a potent analgesic belonging to the pharmacologically diverse 6β-amidoepoxymorphinan group of opioids. We present the synthesis and pharmacological evaluation of five analogs of IBNtxA. The scaffold of IBNtxA was modified by removing the 14-hydroxy group, incorporating a 7,8 double bond and various N-17 alkyl substituents. The structural modifications resulted in analogs with picomolar affinities for opioid receptors. The lead compound (MP1104) was found to exhibit approximately 15-fold greater antinociceptive potency (ED50 = 0.33 mg/kg) compared with morphine, mediated through the activation of kappa- and delta-opioid receptors. Despite its kappa agonism, this lead derivative did not cause place aversion or preference in mice in a place-conditioning assay, even at doses 3 times the analgesic ED50. However, pretreatment with the lead compound prevented the reward behavior associated with cocaine in a conditioned place preference assay. Together, these results suggest the promise of dual acting kappa- and delta-opioid receptor agonists as analgesics and treatments for cocaine addiction.
Authors: Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang Journal: J Med Chem Date: 2009-03-12 Impact factor: 7.446
Authors: Michael H Baumann; Susruta Majumdar; Valerie Le Rouzic; Amanda Hunkele; Rajendra Uprety; Xi Ping Huang; Jin Xu; Bryan L Roth; Ying-Xian Pan; Gavril W Pasternak Journal: Neuropharmacology Date: 2017-08-12 Impact factor: 5.250
Authors: András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar Journal: J Med Chem Date: 2016-09-02 Impact factor: 7.446
Authors: Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell Journal: J Pharmacol Exp Ther Date: 2020-09-10 Impact factor: 4.030
Authors: Abdelfattah Faouzi; Rajendra Uprety; Ivone Gomes; Nicolas Massaly; Attila I Keresztes; Valerie Le Rouzic; Achla Gupta; Tiffany Zhang; Hye Jean Yoon; Michael Ansonoff; Abdullah Allaoa; Ying Xian Pan; John Pintar; Jose A Morón; John M Streicher; Lakshmi A Devi; Susruta Majumdar Journal: J Med Chem Date: 2020-11-10 Impact factor: 7.446
Authors: Tao Che; Susruta Majumdar; Saheem A Zaidi; Pauline Ondachi; John D McCorvy; Sheng Wang; Philip D Mosier; Rajendra Uprety; Eyal Vardy; Brian E Krumm; Gye Won Han; Ming-Yue Lee; Els Pardon; Jan Steyaert; Xi-Ping Huang; Ryan T Strachan; Alexandra R Tribo; Gavril W Pasternak; F Ivy Carroll; Raymond C Stevens; Vadim Cherezov; Vsevolod Katritch; Daniel Wacker; Bryan L Roth Journal: Cell Date: 2018-01-04 Impact factor: 41.582